Characteristics | N=136 | ||
Sex | Male, 64 (47%) | Female, 72 (53%) | |
Biologic agent | Adalimumab, 70 (51%) | Infliximab, 49 (36%) | Both, 17 (13%) |
Age at first biologic prescription | Median, 37 years (range 14–71) | ||
UC/Crohn’s disease/Indeterminate | CD, 89 (65%) | UC, 42 (31%) | IBDI, 5 (4%) |
BRP, biologic review panel; CD, Crohn's disease; IBDI, Indeterminate colitis; UC, ulcerative colitis.